Table 1.
Currently approved immune checkpoint inhibitors (ICI) for cancer immunotherapy.
| Name of ICI | Target | FDA-approved indications | FDA-approved indications |
|---|---|---|---|
| Solid tumors | Hematological malignancies | ||
| Ipilimumab (Yervoy®) |
CTLA-4 | •Melanoma | |
| Nivolumab (Opdivo®) |
PD-1 | •Melanoma •NSCLC •SCLC •Renal cell carcinoma •Squamous cell carcinoma of the head and neck •Urothelial carcinoma •Hepatocellular carcinoma •Esophageal squamous cell carcinoma |
•Classical HL |
| Pembrolizumab (Keytruda®) |
PD-1 | •Melanoma •NSCLC •SCLC •Renal cell carcinoma •Head and neck squamous cell cancer •Urothelial carcinoma •Gastric cancer •Esophageal cancer •Cervical cancer •Endometrial carcinoma •Hepatocellular carcinoma •Merkel cell carcinoma •Microsatellite Instability-High (MSI-H) or mismatch repair deficient cancer* •Tumor Mutational Burden-High* (TMB-H) cancer •Cutaneous squamous cell carcinoma |
•Classical HL •Primary mediastinal large B cell lymphoma |
| Cemiplimab (Libtayo®) |
PD-1 | •Cutaneous squamous cell carcinoma | |
| Ipilimumab + Nivolumab | CTLA-4 + PD-1 | •Melanoma •Renal cell carcinoma •Metastatic colorectal cancer •Hepatocellular carcinoma •NSCLC •Malignant pleural mesothelioma |
|
| Atezolizumab (Tecentriq®) |
PD-L1 | •Melanoma •Urothelial carcinoma •NSCLC •SCLC •Triple-negative breast cancer •Hepatocellular carcinoma |
|
| Avelumab (Bavencio®) |
PD-L1 | •Urothelial carcinoma •Renal cell carcinoma •Merkel cell carcinoma |
|
| Durvalumab (Imfinzi®) |
PD-L1 | •Urothelial carcinoma •NSCLC •SCLC |
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; HL, Hodgkin lymphoma; ICI, immune checkpoint inhibitor; NSCLC, non-small lung cancer; PD-1, programmed cell death protein 1; PD-L1, PD-1 ligand 1; SCLC, small cell lung cancer.
*
Limitation: The safety and effectiveness of pembrolizumab in pediatric patients with MSI-H/TMB-H central nervous system cancers have not been established.